New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
07:16 EDTJAZZJazz consensus expectations too low, says Lazard Capital
Lazard Capital believes consensus expectations for Jazz Pharmaceuticals are too low following the company's Xyrem price increase last week. The firm keeps a Buy rating on the stock with an $87 price target.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
14:00 EDTJAZZFBR Capital to hold a conference
Healthcare Conference to be held in Boston on September 3.
August 25, 2014
12:19 EDTJAZZJazz Pharmaceuticals management to meet with JMP Securities
Subscribe for More Information
August 20, 2014
09:46 EDTJAZZAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use